作者: Alvaro R. Lara , Octavio T. Ramírez
DOI: 10.1007/978-1-61779-433-9_14
关键词:
摘要: Plasmid DNA (pDNA) is the base for promising vaccines and gene therapies against many infectious, acquired, genetic diseases, including HIV-AIDS, Ebola, Malaria, different types of cancer, enteric pathogens, influenza. Compared to conventional vaccines, have advantages such as high stability, not being focusing immune response only those antigens desired immunization long-term persistence vaccine protection. Especially in developing countries, where effective are often unavailable or too expensive, there a need both new improved vaccines. Therefore demand pDNA expected rise significantly near future. Since injection usually leads weak response, several milligrams necessary Hence, special interest raise product yield order reduce manufacturing costs. In this chapter, stages plasmid production reviewed, from vector design downstream operation options. particular, recent advances on cell engineering improving discussed.